Lonza signs manufacturing agreement with Oasmia for ovarian cancer drug

[March 21, 2022]  ZURICH (Reuters) - Lonza Group said on Monday it signed a manufacturing agreement with Sweden's Oasmia Pharmaceutical for ovarian cancer drug candidate Cantrixil that was licensed by Oasmia from the Australian pharmaceutical company Kazia last year.

Under the agreement, Lonza will provide kilogram-scale synthesis, purification, and stability testing of Cantrixil, and deliver cGMP batches of drug substance for clinical supply, the company said in a statement.

The logo of Swiss pharmaceutical group Lonza is seen at its headquarters in Basel, Switzerland March 2, 2020. REUTERS/Arnd Wiegmann/File Photo

Manufacturing is expected to begin this month at Lonza’s recently expanded production facility at Nansha in China, the company said.

(Reporting by Silke Koltrowitz; Editing by Paul Carrel)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.